Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2023
Simcere’s COVID-19 pill goes on sale in China at less than half the price of Pfizer’s Paxlovid
31 January 2023 - The retail price of Simcere Pharmaceutical’s orally taken COVID-19 treatment, which was only approved to go ...
Posted by Michael Wonder on 30 Jan 2023
Alpha Biopharma submits new drug application for zorifertinib, a next generation EGFR-TKI to treat EGFR mutated NSCLC patients with CNS metastases
30 January 2023 - Alpha Biopharma announces that the Center for Drug Evaluation of the NMPA has accepted its new drug ...
Posted by Michael Wonder on 30 Jan 2023
Junshi Biosciences announces approval for marketing of VV116 in China
30 January 2023 - Shanghai Junshi Biosciences announced today that the NMPA has conducted urgent review and approval under special examination ...
Posted by Michael Wonder on 23 Jan 2023
China’s drug pricing policy impedes biotech profits
23 January 2023 - Beijing’s push to boost the sector has been undermined by reimbursement rules. ...
Posted by Michael Wonder on 21 Jan 2023
RemeGen announces two indications for anti-HER2 antibody drug conjugate disitamab vedotin included in China's National Reimbursement Drug List for 2023
20 January 2023 - RemeGen is pleased to announce that as of 18 January 2023, two indications for the Company's ...
Posted by Michael Wonder on 21 Jan 2023
China's first and only approved third generation BCR-ABL inhibitor olverembatinib included into the 2022 National Reimbursement Drug List
18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the ...
Posted by Michael Wonder on 19 Jan 2023
Drugs added to reimbursement list
19 January 2023 - China will add 111 drugs to its national medical reimbursement list this year, with a focus ...
Posted by Michael Wonder on 19 Jan 2023
Innovent announces inclusion in the China National Reimbursement Drug List of Tyvyt in two new indications, olverembatinib for the first listing, Byvadsa, Halpryza and Sulinno in multiple new indications
18 January 2023 - Innovent Biologics today announced that, five products (including new indications) of the company have been included in ...
Posted by Michael Wonder on 18 Jan 2023
Zai Lab announces inclusion of Qinlock (ripretinib) and Nuzyra (omadacycline) in China’s National Reimbursement Drug List
18 January 2023 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...
Posted by Michael Wonder on 18 Jan 2023
HUTCHMED announces agreement with NHSA for inclusion of Orpathys in the National Reimbursement Drug List in China
18 January 2023 - HUTCHMED China today announces, following negotiations with the China National Healthcare Security Administration, Orpathys (savolitinib) has been ...
Posted by Michael Wonder on 18 Jan 2023
BeiGene announces expansion of coverage on China’s National Reimbursement Drug List
18 January 2023 - Four new indications added for tislelizumab and all nine approved indications now included in National Reimbursement Drug List. ...
Posted by Michael Wonder on 18 Jan 2023
Paratek Pharmaceuticals announces inclusion of Nuzyra (omadacycline) in China’s National Reimbursement Drug List (NRDL)
18 January 2023 - National Healthcare Security Administration adds Nuzyra to NRDL for treatment of community-acquired bacterial pneumonia and acute bacterial ...
Posted by Michael Wonder on 17 Jan 2023
China NMPA approves Bio-Thera Solutions’ BAT1806, a biosimilar to Actemra (tocilizumab)
16 January 2023 - World’s first approved biosimilar to Actemra. ...
Posted by Michael Wonder on 16 Jan 2023
China NMPA approved penpulimab for first-line treatment of locally advanced or metastatic quamous NSCLC
15 January 2023 - Akeso announced that the anti PD-1 monoclonal antibody drug penpulimab, co-developed by the Company with Sino ...
Posted by Michael Wonder on 13 Jan 2023
Takeda’s Exkivity (mobocertinib) receives approval from the NMPA of China, becoming the first and only therapy available for patients with EGFR exon20 insertion positive NSCLC
12 January 2023 - Exkivity is the first category-1 innovative drug approved for Takeda China following a Phase 2 global pivotal ...